Latest Breaking News On - Medical oncology - Page 1 : vimarsana.com

U S Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

U S Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Susan spinosaAlexander drilonNick botwoodBristol myers squibbNational cancer instituteDrug administrationExchange commissionBristol myers squibb companyEuropean society for medical oncologyEarly drug development serviceMemorial sloan kettering cancerImportant safety informationMedical oncologyBristol myersBlinded independent central reviewResponse evaluation criteria

U S Food and Drug Administration Approves Augtyrotm (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Augtyrotm (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that.

Bristol myers squibbNick botwoodAlexander drilonSusan spinosaDrug administration approves augtyrotmNational cancer instituteBristol myers squibb companyExchange commissionProduct serviceEuropean society for medical oncologyDrug administrationNext generation tyrosine kinase inhibitorPositive locally advancedMetastatic solidMyers squibbEarly drug development service

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer

Decreases in ctDNA VAF Tied to Improved CBR With Imlunestrant in Pretreated ER+/HER2– Advanced Breast Cancer
onclive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from onclive.com Daily Mail and Mail on Sunday newspapers.

United statesKarthikv giridharBreast cancer congressCancer congressMedical oncologyMayo clinic comprehensive cancer centerBidardf c

Dr Devoe on Safety and Efficacy Data for ELI-002 7P in KRAS+, MRD+ PDAC and CRC

Craig E. Devoe, MD, MS, discusses data for ELI-002 7P in patients with MRD-positive pancreatic and colorectal cancers after locoregional therapy.

Craige devoeOncology serviceRj zuckerberg cancer centerDivision of medical oncologyLong island jewish medical centerShore university hospitalMedical oncologyZuckerberg cancer centerHematology oncology serviceNorth shore university

City of Hope CAR T cell therapy for advanced

City of Hope CAR T cell therapy for advanced
eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.

United statesTanya dorffLos angelesSaul pricemanCell therapy production centerDepartment of medical oncology therapeutics researchProstate cancer foundationDepartment of hematology hematopoietic cell transplantationGenitourinary disease programHematopoietic cell transplantationMedical oncologyNature medicine